Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CEST
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at [email protected]

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
04/27 CELGENE : DE/ Management's Discussion and Analysis of Financial Condition and Re..
04/27 ALLIQUA BIOMEDICAL, INC. (NASDAQ : ALQA) Files An 8-K Entry into a Material Defi..
04/27 STUDIES FROM CELGENE ADD NEW FINDING : Discovery and Structure-Activity...
04/27 CELGENE CO. (NASDAQ : CELG) reported earnings of $1.68 per share beating Walls S..
04/27 CELGENE : tops 1Q profit forecasts
04/27 CELGENE CORPORATION (NASDAQ : CELG) Files An 8-K Results of Operations and Finan..
04/27 CELGENE CORP /DE/ : Results of Operations and Financial Condition, Financial Sta..
04/27 CELGENE : Reports First Quarter 2017 Operating and Financial Results
04/24 CELGENE CORPORATION (NASDAQ : CELG) Cambridge Expansion Drive Gathers Momentum
04/20 CELGENE : FORMA Therapeutics Delivers Two Key Objectives in Collaboration with C..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/28 CELGENE : A Reanalysis Based On Q1 Results And Guidance
04/28 How Low Can You Go? U.S. Pharma Already Shoulders Light Tax Burden
04/28 WALL STREET BREAKFAST : Government Shutdown Looms
04/27 Alexion - Among The Best Risk/Reward In Biotech?
04/27 Celgene (CELG) Q1 2017 Results - Earnings Call Transcript
Advertisement
Financials ($)
Sales 2017 13 211 M
EBIT 2017 7 494 M
Net income 2017 4 610 M
Debt 2017 1 927 M
Yield 2017 -
P/E ratio 2017 21,02
P/E ratio 2018 17,18
EV / Sales 2017 7,48x
EV / Sales 2018 6,20x
Capitalization 96 861 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 142 $
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Scott Andrew Smith President & Chief Operating Officer
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION7.17%96 861
AMGEN, INC.11.70%120 105
GILEAD SCIENCES, INC.-4.27%89 611
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
ACTELION LTD24.13%28 742
More Results